Skip to content
2000
Volume 22, Issue 4
  • ISSN: 1573-4072
  • E-ISSN: 1875-6646

Abstract

Introduction

Dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has captured significant attention in the fields of diabetes, obesity, and cardiovascular research. This scientometric analysis was to identify global trends and hotspots in Dulaglutide research (DGR).

Methods

A comprehensive search of the Scopus database was conducted to retrieve English-language data-driven studies published from the inception of the DGR from 2010 to December 2023. The collected data were subsequently analyzed using VOSviewer and Bibliometrix software. This study sheds light on the intellectual structure of the DGR, which includes identifying key research areas, influential authors, and collaborations, as well as the conceptual structure comprising the identified themes and trends within DGR.

Results and Discussion

The study identified a significant growth in DGR, with the United States, China, and the United Kingdom leading in research output. Canada exhibited strong international collaboration. A small group of highly productive authors contributed disproportionately to the literature, consistent with Lotka’s law. Research trends have evolved from broad themes in cardiovascular health to more specialized studies focusing on the drug’s mechanisms, comparative effectiveness, and emerging applications, such as non-alcoholic fatty liver disease. Citation analysis revealed cardiovascular outcomes, real-world effectiveness, and GLP-1 receptor interactions are among the most researched areas.

Conclusion

DGR is a rapidly expanding field with shifting priorities from general diabetes management to specific pharmacological and clinical outcomes. The findings underscore the need for more diverse geographic representation in research and highlight knowledge gaps that future studies should address. This bibliometric analysis provides valuable insights into the intellectual landscape of Dulaglutide research, aiding future investigations and clinical applications.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cbc/10.2174/0115734072353980250418211500
2025-05-05
2026-03-10

  • From This Site

    /content/journals/cbc/10.2174/0115734072353980250418211500
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. GiorginoF. GuerciB. FüchtenbuschM. LebrecJ. BoyeK. Orsini FedericiM. HeitmannE. DibA. YuM. SapinH. García-PérezL.E. The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.Diabetes Obes. Metab.202325123465347710.1111/dom.15244 37700627
     [Google Scholar]
  2. KimuraT. KatakuraY. ShimodaM. KawasakiF. YamabeM. TatsumiF. MatsukiM. IwamotoY. AnnoT. FushimiY. KameiS. KimuraY. NakanishiS. MuneT. KakuK. KanetoH. Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial (COMING study).Diabetes Obes. Metab.202325123632364710.1111/dom.15258 37646192
     [Google Scholar]
  3. TargherG. MantovaniA. ByrneC.D. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.Lancet Gastroenterol. Hepatol.20238217919110.1016/S2468‑1253(22)00338‑7 36620987
     [Google Scholar]
  4. AbdulredaM.H. Rodriguez-DiazR. CaicedoA. BerggrenP.O. Liraglutide compromises pancreatic β cell function in a humanized mouse model.Cell Metab.201623354154610.1016/j.cmet.2016.01.009 26876561
     [Google Scholar]
  5. NauckM.A. QuastD.R. WefersJ. MeierJ.J. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art.Mol. Metab.20214610110210.1016/j.molmet.2020.101102 33068776
     [Google Scholar]
  6. InagakiN. TakeuchiM. OuraT. ImaokaT. SeinoY. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): A double-blind, multicentre, randomised, phase 3 trial.Lancet Diabetes Endocrinol.202210962363310.1016/S2213‑8587(22)00188‑7 35914543
     [Google Scholar]
  7. GersteinH.C. ColhounH.M. DagenaisG.R. DiazR. LakshmananM. PaisP. ProbstfieldJ. RiesmeyerJ.S. RiddleM.C. RydénL. XavierD. AtissoC.M. DyalL. HallS. Rao-MelaciniP. WongG. AvezumA. BasileJ. ChungN. CongetI. CushmanW.C. FranekE. HancuN. HanefeldM. HoltS. JanskyP. KeltaiM. LanasF. LeiterL.A. Lopez-JaramilloP. Cardona MunozE.G. PiragsV. PogosovaN. RaubenheimerP.J. ShawJ.E. SheuW.H.H. Temelkova-KurktschievT. AbellaM. AlebuenaA. AlmagroS. AmorosoE. AnadonP. AndreuE. AristimuñoG. ArzadunM. BarbieriM. BarcudiR. BartolacciI. BolobanichG. BordonavaA. Bustamante LabartaM. BustosB. CaccavoA. CaminoA. CanteroM. CarignanoM. CartasegnaL. CipulloM. CommendatoreV. ConosciutoV. CostamagnaO. CrespoC. CuelloJ. CuneoC. CusimanoS. DeanS. DituroC. DominguezA. FarahM. FernandezA. FernandezF. FerrariA. FlammiaP. FuentealbaJ. GallardoK.B. GarciaC. Garcia DuranR. GarridoM. GavicolaR. GerbaudoC. GilliG. GiottoA.P. Godoy BolzánP. Gomez VilamajoO. GuerlloyF. GuridiC. Gutierrez GarridoN. HasbaniE. HermidaS. HominalM. HrabarA. IngaramoA. IzzicupoA. KrynskiM. LagruttaM. LanchiottiP. LangheM. LeonardV. LlanosJ. Lopez SantiR. LowensteinJ. LuquezC. MackinnonI. ManaM. ManzurS. MarinoJ. MartellaC. MartinezR. MatiasR. MatkovichJ. MeritanoM. MontañaO. MulazziM. OchoaJ. PaterliniG. PelagaggeM. Peralta LopezM.E. PradoA. PruyasL. RaccaM. RicottiC. RodriguezC. Romero VidomlanskyM. RonderosR. SadowskiA.L. SalaJ. SánchezA. SantoroA. SchiaviL. SeinM. SerniaV. SerraL. SicerM. SmithT. SosoL. SposettiG. SteinacherA. StivalJ. TedescoJ. ToninH. TortoloM. UllaM. VallejosJ. VicoM. VirgillitoL. ViscoV. VogelD. WaismanF. ZaidmanC. ZucchiattiN. BadshahI. CohenN. ColmanP. ColquhounD. DavisT. FourlanosS. FulcherG. HamlynJ. HaywoodC. HockingS. HuchinsonM. JeffriesW. KylM. LoC. MahP.M. MakepeaceA. MaropeD. NanayakkarN. NankervisA. PalmerN. PalolusB. PillaiS. PriceS. PriceS. ProiettoJ. ReutensA. RodrigoN. SheikhA. SmithG. SoM. SoldatosG. StuckeyB. SumithranP. TeedeH. VoraP. WilliamsL. AbibE. Adão PoçoC. AlvesÉ.F. Andreatta Bernardi BareaJ. Avezum OliveiraL. CastroD.L.C. Correa da CruzI. CostaM. CruzI. CunhaS. Da SilvaM.A.V. de Carvalho Camara BonaR. de PaulaB. EliaschewitzF. FazolliG. Ferreira FilhoC.A. FortesJ. FrançaC. FrancoD.R. GenestretiP.R. GiorgetoF. GonçalvesR.M. GrossmanM.E. Henrique MarcelinoA.C. HernandesM. HortaA. JaegerC. KaneblaiM. Kauffman RutenbergC. Kerr SaraivaJ.F. LemosM.A. MaiaL. ManentiE.R. MarquesM. Melissa ValerioC. MoreiraR. MothéF. MoucoO.M. MouraP. Moura JorgeJ.C. NakashimaC. NakazoneM. NapoliT. NunesC. Nunes SallesJ.E. OliveiraK. OliveiraM. PantanoG.S. PetriF. PiazzaL. PiresA.C. PizzatoP. PrataS. PrecomaD. RechR. ReisG. ReisH. ResendeE. Ribas FortesJ. RodovalhoS. Rossi dos SantosF. SallesJ.E. SampaioC.R. SantosT. Santos dos SantosV. Silva e QuadrosT. SilveiraD. SiqueiraK.N. TeireiraM. UeharaM. ValerioC. ViannaH. VidottiM.H. ViscontiG.L. ZanellaM.T. AndreevaV. BorisovR. BotushanovN. DimitrovG. DimovaK. DragoychevT. GrigorovaV. GushterovaV. IvanovI. KocelovaT. KurktschievD. MiletievaM. Nenkova-GugushevaN. PanchevaR. PavlovaM. RaevD. SpasovaV. StoikovA. TroevD. YanevT. Yoncheva-MihaylovaM. AbitbolA. AjalaB. AlguwaihesA. ArdilouzeJ-L. Aris-JilwanN. ArnaoutA. AronsonR. AslamN. BabinS. BailargeonJ-P. BaileyA. BajajH. BeauchesneC. BecaS. BelangerA. BellA. BellabarbaD. BerardL. BerenbaumB. BergeronV. BerlingieriJ. BernierF. BisharaP. BlankD. BlumerI. BraultS. BretonD. CarpentierA. ChaJ. ChandraP. ChiassonJ-L. ConwayJ.R. CoutureG. CoutureN. DagenaisG. DattaD. D’IgnazioG. DumasR. FayD. FrechetteA. FrenetteL. FungD. GagnonN. GalterM. GaronJ. GauthierJ.S. GeadahC. GilbertJ. GirardR. GoldenbergR. GrossmanL.D. GuptaN. HalleJ-P. HivertMF. HoudeG. HouldenR. HramiakI. JablonskiT. JainA.J. KhandwalaH. KhoslaM. LachanceC. LaflammeE. LangloisM-F. LariveeL. LiutkusJ. LochnanH. MalikS. McDonaldC. MehtaP. MihailidisJ. MilotA. NarulaP. NaultP. NayarA. NiskerW. OuelletG. PalardyJ. PatelM. PaulT. PedersenS. PerronP. PesantM-H. PoirierP. PoulinM-C. PunthakeeZ. RehmanW. RossS. SagarP. SalibaN. SandlerS. SchiffrinA. SchlosserR. Seth-SharmaA. ShermanM. SionitD. SivakumarT. SotoJ. St-AmourE. SteenO. SussmanJ. TelnerA. TobeS. Twum-BarimaD-Y. Van ZantenA. VanRossumN. VecchiarelliJ. WardR. WessengelJ. WeisnagelS. WildermanI. WooV. YakubovichN. YaleJ-F. YaredZ. AcevedoM. AguirreM.L. AizmanA. BarrosoM.S. CobosL. Danin VargasA. DescalziB. GodoyG. GrumbergE. LahsenR. LarenasG. OrtizE. ParedesJ. PotthoffS. RetamalE. RojasL. SalgadoM. SantibanezC. SolisC. StokinsB. AcciniJ. AcebedoJ. Agudelo BaenaL.M. AlarconS. AngelJ. ArcosE. Aroca MartinezM. AtuestaL. BalagueraJ. BallestasD. BarreraS.I. Barrios ReyesR. BayonaA. BermudezA. BernalD.Z. BlanquicettM. BravoV. BuenoW. Burbano DelgadoA. CadenaA. CadenaA. CaicedoS. CeleminC. ConsuegraR. Contreras PimientaC. CorredorK.J. CureC. De La Hoz RuedaL.D. DelgadoE. DiazS. DiegoM. DonadoA. Encinales SanabriaW. EscobarJ. EscorciaG. ForeroL. FuentesL. GarciaM. Garcia LozadaH. Garcia OrtizL. GiraldoA. Gomez GonzalezL. GranadaJ. GutierrezC. HenaoN. HernandezE. Herrera UejbeO.M. Higuera CobosJ.D. Ibarra GómezJ. JaimesE.H. JaramilloM. JaramilloN. Jaramillo GomezC. Jaramillo SanchezM. Jarava DuránI. Lopez CeballosC. MadridC. María AmasthaE. MercadoJ. MolinaD.I. Molina SotoJ. MontoyaC. MoralesA. MuñozC. OrozcoL.A. OsorioO. Palmera SanchezJ.M. PeñaA. PerezJ. Perez AgudeloJ. Pérez AmadorG. PertuzC. PosadaI. PuertaC. QuinteroA. QuirozD. RendonC. ReyesA. ReyesA. RipollD. RiveraC. RochaM. RodriguezJ.F. Rodriguez VillanuevaK.A. Rodriguez ZabalaJ.E. RojasS. RomeroM. RoseroR. Rosillo CardenasA.R. RuedaL. SanchezG. SanchezT. Sotomayor HerazoA. SuarezM. TorresM. TrujilloF. UrinaM. Van StrahlenL. VelandiaC. Velasquez GuzmanC. VelazquezE. Vidal PradaT. Yepez AlvaranJ.P. ZarateD. AndelovaJ. BenesovaR. BuzovaB. CechV. ChodovaI. ChouraM. DufkaA. GamovaA. GorgolJ. HalaT. HavlovaH. HlavkovaD. HoranskaP. Ilcisin-ValovaJ. JenickovaP. JerabekO. KantorovaI. KolomaznikovaK. KopeckovaI. KopeckovaM. LinhartK. LinhartT. MalechaJ. MalicherovaE. NeubauerovaD. OznerovaM. PartysR. PederzoliovaE. PetrusovaM. PrymkovaV. RacickaE. ReissovaI. RoderovaE. StanekL. StriovaA. SvarcovaD. SvobodaP. Szeghy MalicharovaE. UrgeJ. VeselyL. WasserburgerB. WasserburgerovaH. ZahumenskyE. ZamrazilV. AlawiH. AnastasiadisE. AxthelmE. BielerT. BuhrigC. DegtyarevaE. DellannaF. DerwahlK-M. DiesselS. DogiamiB. Dorn-WeitzelK. ErnstM. FaulmannG. FetscherB. ForstT. Freyer-LahresG. FunkeK. GanzX. GleixnerC. HanefeldC. HeinrichsS. HellebergS. HenkelE. HetzelG.R. HoffmannC. JacobF. JacobS. JohnF. JonczykA. KamkeW. KleinC. KleinhardtM. KleophasW. KoschC. KreutzmannK. KühnA. Lee-BarkeyY.H. LierA. MaatoukS. MinnichJ. MitryM. MuessigI. NiculaD. NiemannM. NothroffJ. OttP. PfuetznerA. PfütznerA. PistroschF. PohlW. ProchazkovaZ. RetkowskaM. RosinH. SachsenheimerD. SamerH. SanuriM. SchaeferA. SchaperF. SchulzeE-D. SchulzeM. SchumannM. SegietT. SowaV. StahlH-D. SteinfeldtF. TeigeM. TriebB. TschoepeD. UebelP. WarkenB. WeigmannI. WeylandK. WilhelmK. BaloT. BalsayM. BendeI. BezzeghK. BirkusZ. BudayB. CsomaiM. DeakL. DezsoE. FaludiP. FaluvegiM. FazekasI. FeherA. FejerC. FintaE. FulczA. GaalZ. GurzoM. HatiK. HerczegG. JozsefI. JuhaszM. KeltaiK. KoranyiL. KulcsarE. KunK. LaczkoA. Literáti-NagyB. MezoI. MilederM. MoriczI. NagyK. NagybaczoniB. NemethC. OzeA. PauerJ. PeterfaiE. PolocsanyiB. PoorF. ReiberI. SalamonC. SebestyenJ. TorokI. TuuM. VargaA. VassV. AhnC.M. AhnC. ByungWonP. ChangH-J. ChangK. ChoiE-Y. ChoiH.S. ChungJ-W. HongB-K. HongY.J. HyonM.S. JeongM.H. KangS. KimB-K. KimJ-H. KimJ.H. KimK-S. KimK-S. KimM.H. KimP-J. KimS-K. KimY-S. KimY.K. KohY.S. KwonH.M. LeeB.K. LeeB-W. LeeJ.B. LeeM-M. LimY-M. MinP.K. ParkJ.S. ParkJ. ParkK.H. ParkS. PyunW.B. RimS.J. RyuD-R. SeoH-S. SeungK.B. ShinD-H. SimD.S. YoonY.W. AndersoneI. BabickaK. BalcereI. BaronsR. CapkovskaI. GeldnereK. GriganeI. JegereB. LagzdinaI. MoraL. PastareS. RitenbergaR. RomanovaJ. SakniteI. SidlovskaN. SokolovaJ. SteinaS. StrizkoI. TeterovskaD. VizinaB. BarsieneL. BelozarieneG. Daugintyte-PetrusieneL. DrungilieneN. GarsvieneN. GrigieneA. GrizasV. JocieneV. KalvaitieneD. KaupieneJ. KavaliauskieneJ. KozlovieneD. LaptevaI. ManeikieneB. MarcinkevicieneJ. MarkauskieneV. MeilunieneS. NorkusA. NorvilieneR. PetrenkoV. RadzevicieneR. SakalyteG. UrbonasG. UrbutieneS. VasiliauskasD. VelickieneD. AguilarC. AlcocerM. Avalos-RamirezJ.A. Banda-ElizondoR. Bricio-RamirezR. Cardenas MejiaK. CavazosF. ChapaJ. CienfuegosE. De la PeñaA. de la Peña TopeteG. De los Rios IbarraM.O. EliasD. Flores-MorenoC. Garcia HernandezP. GonzalezL.G. Guerra MoyaR.L. Guerra-LopezA. Hernandez BaylonR. Herrera ColoradoC. Herrera-MarmolejoM. Islas-PalaciosN. LopezE. LopezF. Lopez AlvaradoA. Luna CeballosR.I. Morales VillegasE. Moreno-VirgenG. Parra PerezR.L. Pascoe GonzalezS. Peralta-CantuI. PrevinR. RamirezR. RamirezR. Ramos ZavalaM.G. RodriguezM. Salgado-SedanoR. Sanchez-AguilarA.C. Santa Rosa FrancoE. Sauque-ReynaL. Suarez OteroR. TorresI. Velarde-HarnandezE. VillagordoaJ. Villeda-EspinozaE. Vital-LopezJ. Zavala-BelloC.J. BakerJ. Barrington-WardE. BrownlessT. CarrollR. CarsonS. ChoeM. CorinA. CorleyB. CutfieldR. DalamanN. DixonP. DruryP. DysonK. FlorkowskiC. FordM. FrengleyW. HelmC. KatzenC. KerrJ. KhanolkarM. KimD. KoopsR. KrebsJ. LeikisR. LowK. LuckeyA. LukeR. MacaulayS. MarksR. McNamaraC. Millar-CooteD. MillerS. MottersheadN. ReidJ. RobertsonN. RosenI. RoweD. SchmiedelO. ScottR. SebastianJ. SheahanD. StiebelV. TernouthI. TofieldC. VenterD. WilliamsM. WilliamsM. WuF. YoungS. ArciszewskaM. BochenekA. BorkowskiP. BorowyP. ChrzanowskiT. CzerwinskiE. DwojakM. GrodzickaA. JaniecI. JarugaJ. Jazwinska-TarnawskaE.K. JedynastyK. Juzwiak-CzapiewskaD. Karczewicz-JanowskaJ. KoniecznyJ. KoniecznyM. KorolM. KozinaM. KrzyzagorskaE. Kucharczyk-PetrykaE. LazR. MajchrzakA. MrozowskaZ. MularczykM. NowackaE. PeczynskaJ. PetrykaR. PietrzakR. Pisarczyk-WizaD. RozanskaA. RuzgaZ. RzeszotarskaE. SachaM. SekulskaM. Sidorowicz-BialynickaA. StasinskaT. Strzelecka-SosikA. SwierszczT. SzymkowiakK.M. TurowskaO. WisniewskaK. WizaM. WozniakI. ZelazowskaK. Ziolkowska-GawronB. Zytkiewicz-JarugaD. AlbotaA. AlexandruC. AvramR. BalaC. BarbontaD. BarbuR. BraicuD. CalutiuN. CatrinoiuD. CerghizanA. CiorbaA. CraciunA. DorosR. DumaL. DumitracheA. FerariuI. Ferician MozaA. GherganA. GhiseG. GraurM. GribovschiM. MihaiB. MihalacheL. MihalceaM. MindrescuN. MorosanuM. MorosoanuA. MotaM. MozaA. NafornitaV. NateaN. NicodimS. NitaC. OnacaA. OnacaM. PopC. PopL. PopaA. PopescuA. PrunaL. RomanG. RosuM. SimaA. SipciuD. Sitterli-NateaC.N. SzilagyiI. TapuricaM. TaseA. TutescuA-C. VanghelieL. VerdeI. VladA. ZarnescuM. AkhmetovR. AllenovaI. AvdeevaI. BaturinaO. BiserovaI. BokovinN. BondarI. BurovaN. ChufenevaG. ChumachekE. DemidovaM. DeminA. DrobyshevaV. EgorovaI. EsenyanL. GeligE. GilyarevskyS. GolshmidM. GoncharovA. GorbunovaA. GordeevI. GorelyshevaV. GoryunovaT. GrebenshchikovaI. IlchenkoR. IvannikovaM. KarabalievaS. KarpeevaJ. KhaykinaE. KobalavaZ. KononenkoI. KorolikO. KorshunovaA. KostenkoV. KrasnopevtsevaI. KrylovaL. KulkovaP. KuzminaI. LedyaevaA. LevashovS. LokhovininaN. LvovV. MartirosyanN. NedogodaS. NilkR. OsmolovskayaY. PanovA. ParamonovaO. PavlovaE. PekarevaE. PetuninaN. PonamarevaS. ReshedkoG. SalasyukA. SepkhanyanM. SerebrovA. ShabelnikovaO. SkvortsovA. SmirnovaO. SpiridonovaO. StrogovaS. TaratukhinE. TereschenkoS. TrukhinaL. TsarkovaO. TsomaV. TumarovF. TyanN. TyurinaT. VillevaldeS. YankovayaE. ZarutskayaL. ZenkovaE. BadatA. BesterF. BlignautS. BlomD. BooysenS. BoydW. BriceB. BrownS. BurgessL. CawoodR. CoetzeeK. ConradieH. CronjeT. de JongD. EllisG. EmanuelS. EngelbrechtI. FoulkesS. FourieD. GibsonG. GovenderT. HansaS. HemusA.C. HendricksF. HeradienM. HolmgrenC. HoosainZ. HorakE. HowardJ. ImminkI. JanariE. JivanD. KlusmannK. LabuschagneW. LaiY. LatiffG. LombaardJ. LotteringH. MeedingR. MiddlemostS. MithaH. MithaI. MkhwanaziS. MoodleyR. MurrayA. MusungaieD. OsmanY. PeaceyK. Pillay-RamayaL. PretoriusC. ProzeskyH. SarvanM. ScholtzE. SebestenyA. SkinnerB. SkrikerM. SmitM. StapelbergA-M. SwanepoelN. UrbachD. van AswegenD. van ZylF. Van ZylL. VenterE. WadvallaS. WingJ. WolmaransK. AbreuC. AguilàP. AguileraE. AlonsoN. AlvarezC. CajasP. CastroJ.C. CodinachsR. ContrerasJ. CovesM.J. FajardoC. FerrerJ.C. FontN. GarciaM. GilM.A. GomezF. GomezL.A. GonzalbezJ. GrieraJ.L. MasmiquelL. MauricioD. Narejos PerezS. NicolauJ.A. Noheda ContrerasO. OlivanJ. OlivaresJ. OrtegaE. PelliteroS. PertusaS. RiusF. RodriguezI. Sánchez-JuanC. SantosD. SoldevilaB. SubiasD. TernsM. TrescoliC. VilaplanaJ. VillanuevaA. AlboJ. AntusK. AxelssonM. BergströmL. Binsell-GerdinE. BomanK. BotondF. DotevallA. GraipeA. JarnetC. KaminskaJ. KempeA. KorhonenM. LinderfalkC. LiuB. LjungstroemK. LjungströmK. MalmqvistL. MellbinL. MooeT. NicolP. NorrbyA. OhlssonA. RosengrenA. SaafJ. SalmonssonS. StrandbergO. SvenssonK-A. TengmarkB-O. TsatsarisG. UlvenstamA. VaskoP. ChangC-T. ChangH-M. ChenJ-F. ChenT-P. ChungM-M. FuC-P. HsiaT-L. HuaS-C. KuoM-C. LeeC. LeeI-T. LiangK-W. LinS.Y. LuC-H. MaW-Y. PeiD. ShenF-C. SuC-C. SuS-W. TaiT-S. TsaiW-N. TsaiY-T. TungS-C. WangJ-S. YuH-I. Al-QaissiA. ArutchelvamV. AtkinS. AuS. AyeM.M. BainS. BejnariuC. BellP. BhatnagarD. BilousR. BlackN. BrennanU. BrettB. BujanovaJ. ChowE. CollierA. CombeA. CourtneyC. CourtneyH. CrothersJ. EavisP. ElliottJ. FebbraroS. FinlaysonJ. GandhiR. GillingsS. HamlingJ. HarperR. HarrisT. HassanK. HellerS. JaneA. JavedZ. JohnsonT. JonesS. KennedyA. KerrD. KilgallonB. KonyaJ. LindsayJ. Lomova-WilliamsL. LookerH. MacFarlaneD. MacruryS. MalikI. McCrimmonR. McKeithD. McKnightJ. MishraB. MukhtarR. MulliganC. O’KaneM. OlatejuT. OrpenI. RichardsonT. RooneyD. RossS.B. SathyapalanT. SiddaramaiahN. SitL.E. StephensJ. TurtleF. WakilA. WalkinshawE. AliA. AndersonR. ArakakiR. ArefO. ArianiM.K. ArkinD. BanarerS. BarchiniG. BhanA. BranchK. BrautigamD. BrietzkeS. BrinasM. BritoY. CarterC. CasagniK. CasulaS. ChakkoS. CharatzS. ChildressD. ChowL. ChusteckaM. ClarkeS. CohenL. CollinsB. Colon VegaG. Comulada-RiveraA. Cortes-MaisonetG. DavisM. de SouzaJ. DesouzaC. DinnanM. Duffy-HidalgoB. DunnB. DunnJ. ElmanM. FelicettaJ. FinkelsteinS. Fitz-PatrickD. FlorezH. ForkerA. FowlerW. FredricksonS. FreedmanZ. Gainey NarronB. Gainey-FerreeK. GardnerM. GastelumC. GiddingsS. GillespieE. GimnessM.P. GoldsteinG. GomesM. GomezN. GormanT. GoswamiK. GravesA. HackingS. HallC. HansonL. HarmanS. HeberD. HenryR. HinerJ. HirschI. HollanderP. HookerT. HorowitzB. HosteL. HuangL. HuynhM. HymanD. IdrissS. IranmaneshA. KarounosD. KashyapM. KatzL. KayeW. KhaitonY. KhardoriR. KitchenT. KleinA. KnffemW. KosiborodM. KreglingerN. KrugerD. KumarA. LaboyI. LarrabeeP. LarrickL. LawsonD. LedetM. LenhardJ. LevyJ. LiG. LiZ. LiebD. LimcoliocA. Lions-PattersonJ. LorberD. LorchD. LorrelloM. LuP. LucasK.J. MaS-L. MacAdamsM. MageeM. MagnoA. MahakalaA.R. MarksJ. McCallA. McClanahanW. McClaryC. MelendezL. MelishJ. MichaudD. MillerC. MillerN. MoraP. MotenM. MudaliarS. MyrickG. NarayanP. NassifM. NeriK. NewtonT. NiblackP. NicolP. NyenweE. OdugbesanA.O. OkorochaY. Ortiz CarrasquilloR. OseiK. PalermoC. PatelH. PatelK. PauC. PerleyM. PlevinS. PlummerE. PowellR. QintarM. RawlsR. Reyes-CastanoJ. ReynoldsL. RichardsR. RosenstockJ. RoweC. SalehJ. SamS. SanchezA. SanderD. SandersonB. SavinV. SeaquistE. ShahJ. ShiS. ShivaswamyV. ShlotzhauerT. ShoreD. SkukowskiB. SoeK. SolheimV. SouferJ. SteinbergH. SteinsapirJ. TarkingtonP. ThayerD. ThomsonS. ThrasherJ. TibaldiJ. TjadenJ. ToresO. TrenceD. TrikudanathanS. UllalJ. UwaifoG. VoA. VuK. WaliaD. WeilandK. WhitehouseF. WiegmannT. WyneK. WynneA. YuenK. ZaretzkyJ. ZebrackJ. ZieveF. ZigrangW. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial.Lancet20193941019312113010.1016/S0140‑6736(19)31149‑3 31189511
     [Google Scholar]
  8. MohananP.P. JariwalaP. How did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio centricity.Indian Heart J.20237511810.1016/j.ihj.2022.11.010 36435205
     [Google Scholar]
  9. KarakasisP. PatouliasD. PamporisK. StachteasP. BougioukasK.I. KlisicA. FragakisN. RizzoM. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: Systematic review and meta-analysis of randomized controlled trials.Metabolism202314915571010.1016/j.metabol.2023.155710 37852529
     [Google Scholar]
  10. DarrajH. BadediM. PooreK.R. HummadiA. KhawajiA. SolanY. ZakriI. SabaiA. DarrajM. MutawwamD.A. DaghreeriM. SayedS. AlaallahW. AlfadhlyA. AlsabaaniA. Vitamin D deficiency and glycemic control among patients with type 2 diabetes mellitus in Jazan City, Saudi Arabia.Diabetes Metab. Syndr. Obes.20191285386210.2147/DMSO.S203700
     [Google Scholar]
  11. ShuY. HeX. WuP. LiuY. DingY. ZhangQ. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.Front. Public Health20221099617910.3389/fpubh.2022.996179 36339230
     [Google Scholar]
  12. RileyL. CahillA. BeigiR. SavichR. SaadeG. Improving safe and effective use of drugs in pregnancy and lactation: Workshop summary.Am. J. Perinatol.201734882683210.1055/s‑0037‑1598070 28142152
     [Google Scholar]
  13. WangW. YanX. ChengZ. ZhangQ. WangR. DengY. MaJ. ZhuD. Efficacy and safety of adding once‐weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD‐CHN3): A randomized, double‐blind, placebo‐controlled, phase III trial.Diabetes Obes. Metab.202325123690369910.1111/dom.15263 37732487
     [Google Scholar]
  14. AlkhammashR. Bibliometric, network, and thematic mapping analyses of metaphor and discourse in COVID-19 citations from 2020 to 2022.Front. Psychol.202313106294310.3389/fpsyg.2022.1062943 36726506
     [Google Scholar]
  15. ShouX. WangY. DuanC. YuanG. WeiN. YangY. HuY. Knowledge domain and emerging trends of glucagon-like peptide 1 receptor agonists in cardiovascular research: A bibliometric analysis.Curr. Probl. Cardiol.202348810119410.1016/j.cpcardiol.2022.101194 35395332
     [Google Scholar]
  16. DagliN. KumarS. AhmadR. NarwariaM. HaqueM. An update on Semaglutide research: A bibliometric analysis and a literature review.Cureus20231510e4651010.7759/cureus.46510 37808605
     [Google Scholar]
  17. BurnhamJ.F. Scopus database: A review.Biomed. Digit. Libr.2006311810.1186/1742‑5581‑3‑1 16522216
     [Google Scholar]
  18. AriaM. CuccurulloC. Bibliometrix: An R-tool for comprehensive science mapping analysis.J. Informetrics201711495997510.1016/j.joi.2017.08.007
     [Google Scholar]
  19. van EckN.J. WaltmanL. Software survey: VOSviewer, a computer program for bibliometric mapping.Scientometrics201084252353810.1007/s11192‑009‑0146‑3 20585380
     [Google Scholar]
  20. AfuyeG.A. KalumbaA.M. BusayoE.T. OrimoloyeI.R. A bibliometric review of vegetation response to climate change.Environ. Sci. Pollut. Res. Int.20212021113 34697705
     [Google Scholar]
  21. BorgohainD.J. VermaM.K. NazimM. SarkarM. Application of Bradford’s law of scattering and Leimkuhler model to information science literature.COLLNET J. Scient Inform. Manag.202115119721210.1080/09737766.2021.1943041
     [Google Scholar]
  22. BérdiM. Bibliometric analysis of Hungarian-related citations in suicidal behavior research of the last three decades.Psychiatr. Hung.2023383189202 37982267
     [Google Scholar]
  23. GanasegeranK. HorC.P. JamilM.F.A. SuppiahP.D. NoorJ.M. HamidN.A. ChuanD.R. ManafM.R.A. Ch’ngA.S.H. LooiI. Mapping the scientific landscape of diabetes research in Malaysia (2000-2018): A systematic scientometrics study.Int. J. Environ. Res. Public Health202118131810.3390/ijerph18010318 33406730
     [Google Scholar]
  24. AtlasiR. Tabatabaei-MalazyO. BandarianF. RezaeiN. KhashayarP. LarijaniB. Scientometric analysis of global scientific citations on COVID-19 and diabetes with an emphasis on middle eastern countries.Int. J. Endocrinol. Metab.2022203e12081210.5812/ijem‑120812 36407029
     [Google Scholar]
  25. BoyeK.S. LebrecJ. DibA. HeitmannE. FedericiM.O. YuM. SapinH. BarrettA. GuerciB. GiorginoF. FüchtenbuschM. García-PérezL.E. The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): Final patient‐reported outcomes at 24 months.Diabetes Obes. Metab.202325123453346410.1111/dom.15145 37712754
     [Google Scholar]
  26. GiorginoF. YuM. HauptA. MilicevicZ. García-PérezL.E. Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial.Diabetes Obes. Metab.201921112570257510.1111/dom.13844 31364266
     [Google Scholar]
  27. MatzaL.S. BoyeK.S. StewartK.D. CoyneK.S. WullenweberP.K. CuttsK.N. JordanJ.B. WangQ. YuM. CurrieB.M. MalleyK.G. IshakK.J. HietpasR.T. García-PérezL.E. Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).Diabetes Obes. Metab.202022335536410.1111/dom.13902 31646727
     [Google Scholar]
  28. ModyR. HuangQ. YuM. ZhaoR. PatelH. GrabnerM. LandóL.F. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States.Diabetes Obes. Metab.201921492092910.1111/dom.13603 30520248
     [Google Scholar]
  29. ModyR. YuM. GrabnerM. BoyeK. TengC.C. KwanA.Y.M. Dulaglutide shows sustained reduction in Glycosylated hemoglobin values: 2-Year US Real-world study results.Clin. Ther.202042112184219510.1016/j.clinthera.2020.09.011 33256915
     [Google Scholar]
  30. ModyR. YuM. NepalB. KonigM. GrabnerM. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise:] 6-month follow‐up from US real‐world data.Diabetes Obes. Metab.202123110611510.1111/dom.14195 32945083
     [Google Scholar]
  31. YuM. YuanG.Y. ZhangB. WuH.Y. LvX.F. Efficacy and safety of dulaglutide by baseline hba1c in chinese patients with type 2 diabetes: A post Hoc analysis.Diabetes Ther.20201151147115910.1007/s13300‑020‑00804‑2 32277401
     [Google Scholar]
  32. ElfakiF.A. ChandikaR.M. KahlaniS.H. HakamiH.H. HakamiA.S. AlsayeghA.A. DighririA.Y. KhalafallaH.E. Dietary patterns and their associations with glycemic control among type 2 diabetic patients in Jazan, Saudi Arabia: A cross-sectional study.Medicine (Baltimore)202310228e3429610.1097/MD.0000000000034296 37443467
     [Google Scholar]
  33. ScheenA.J. Dulaglutide for the treatment of type 2 diabetes.Expert Opin. Biol. Ther.201717448549610.1080/14712598.2017.1296131 28274140
     [Google Scholar]
  34. NauckM. WeinstockR.S. UmpierrezG.E. GuerciB. SkrivanekZ. MilicevicZ. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).Diabetes Care20143782149215810.2337/dc13‑2761 24742660
     [Google Scholar]
  35. UmpierrezG. Tofé PovedanoS. Pérez ManghiF. ShurzinskeL. PechtnerV. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).Diabetes Care20143782168217610.2337/dc13‑2759 24842985
     [Google Scholar]
  36. WyshamC. BlevinsT. ArakakiR. ColonG. GarciaP. AtissoC. KuhstossD. LakshmananM. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).Diabetes Care20143782159216710.2337/dc13‑2760 24879836
     [Google Scholar]
  37. ChangK.C. ShaoS.C. KuoS. YangC.Y. ChenH.Y. ChanY.Y. OuH.T. Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: A multi-institutional cohort study and meta-analysis.Cardiovasc. Diabetol.202019117210.1186/s12933‑020‑01148‑8 33036617
     [Google Scholar]
  38. MengY. WangY. FuW. ZhangM. HuangJ. WuH. SunL. Global trends and focuses of GLP-1RA in renal disease: A bibliometric analysis and visualization from 2005 to 2022.Naunyn Schmiedebergs Arch. Pharmacol.2023396123347336110.1007/s00210‑023‑02575‑6 37389601
     [Google Scholar]
  39. JendleJ. GrunbergerG. BlevinsT. GiorginoF. HietpasR.T. BotrosF.T. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: A comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.Diabetes Metab. Res. Rev.201632877679010.1002/dmrr.2810 27102969
     [Google Scholar]
  40. NichollsS.J. BhattD.L. BuseJ.B. PratoS.D. KahnS.E. LincoffA.M. McGuireD.K. NauckM.A. NissenS.E. SattarN. ZinmanB. ZoungasS. BasileJ. BarteeA. MillerD. NishiyamaH. PavoI. WeerakkodyG. WieseR.J. D’AlessioD. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics.Am. Heart J.202426711110.1016/j.ahj.2023.09.007 37758044
     [Google Scholar]
  41. SohnM. FriasJ.P. LimS. Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials.Diabetes Obes. Metab.202325123560357710.1111/dom.15251 37649320
     [Google Scholar]
  42. KristensenS.L. RørthR. JhundP.S. DochertyK.F. SattarN. PreissD. KøberL. PetrieM.C. McMurrayJ.J.V. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.Lancet Diabetes Endocrinol.201971077678510.1016/S2213‑8587(19)30249‑9 31422062
     [Google Scholar]
  43. SattarN. LeeM.M.Y. KristensenS.L. BranchK.R.H. Del PratoS. KhurmiN.S. LamC.S.P. LopesR.D. McMurrayJ.J.V. PratleyR.E. RosenstockJ. GersteinH.C. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials.Lancet Diabetes Endocrinol.202191065366210.1016/S2213‑8587(21)00203‑5 34425083
     [Google Scholar]
  44. CamilleriM. AcostaA. Newer pharmacological interventions directed at gut hormones for obesity.Br. J. Pharmacol.2023181811531164 37917871
     [Google Scholar]
  45. LiY. GongX. GămanM.A. Hernández-WoltersB. VeluP. LiY. The effect of subcutaneous dulaglutide on weight loss in patients with Type 2 diabetes mellitus: Systematic review and meta‐analysis of randomized controlled trials.Eur. J. Clin. Invest.2024544e1412510.1111/eci.14125 37950521
     [Google Scholar]
  46. ShandJ.A.D. YoungS. VersterF. PetersC. Pilot study to test the safety, tolerability and feasibility of dulaglutide during a low-energy diet for weight loss and improved glycaemic control.BMJ Nutr. Prev. Health20236234134610.1136/bmjnph‑2023‑000733 38264361
     [Google Scholar]
  47. MuzurovićE.M. VolčanšekŠ. TomšićK.Z. JanežA. MikhailidisD.P. RizzoM. MantzorosC.S. Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes, and non-alcoholic fatty liver disease-current evidence.J. Cardiovasc. Pharmacol. Ther.2022271074248422114637110.1177/10742484221146371 36546652
     [Google Scholar]
  48. KaragiannisT. AvgerinosI. LiakosA. Del PratoS. MatthewsD.R. TsapasA. BekiariE. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis.Diabetologia20226581251126110.1007/s00125‑022‑05715‑4 35579691
     [Google Scholar]
  49. JanzenK.M. SteuberT.D. NislyS.A. GLP-1 agonists in type 1 diabetes mellitus.Ann. Pharmacother.201650865666510.1177/1060028016651279 27252246
     [Google Scholar]
  50. KielgastU. HolstJ. MadsbadS. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.Curr. Diabetes Rev.20095426627510.2174/157339909789804413 19925391
     [Google Scholar]
  51. JepsenM.M. ChristensenM.B. Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.Expert Opin. Emerg. Drugs202126323124310.1080/14728214.2021.1947240 34176426
     [Google Scholar]
  52. EkhlasiM. TaheriS. YousefiN. Cost-effectiveness of dulaglutide versus liraglutide for management of type 2 diabetes mellitus in Iran.Value Health Reg. Issues202232546110.1016/j.vhri.2022.07.005 36087364
     [Google Scholar]
  53. ViljoenA. ChubbB. MalkinS.J.P. BerryS. HuntB. BainS.C. The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.Eur. J. Health Econ.202324689590710.1007/s10198‑022‑01514‑1 36114904
     [Google Scholar]
  54. YuanS. WuY. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: A micro-simulation model.Front. Public Health202311120181810.3389/fpubh.2023.1201818 37744474
     [Google Scholar]
  55. BrooksA. LangerJ. TervonenT. HemmingsenM.P. EguchiK. BacciE.D. Patient preferences for GLP-1 receptor agonist treatment of type 2 Diabetes Mellitus in Japan: A discrete choice experiment.Diabetes Ther.201910273574910.1007/s13300‑019‑0591‑9 30847838
     [Google Scholar]
  56. GelhornH. BacciE.D. PoonJ.L. BoyeK. SuzukiS. BabineauxS.M. Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan.Patient Prefer. Adherence2016101337134810.2147/PPA.S109289 27524889
     [Google Scholar]
  57. GelhornH. PoonJ.L. DaviesE. PaczkowskiR. CurtisS. BoyeK.S. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK.Patient Prefer. Adherence201591611162210.2147/PPA.S90842 26635470
     [Google Scholar]
  58. Liebisch-ReyH. Suarez-ChaconA.M. FuentesY.V. BlancoJ. KockJ. Lechtig-WassermannS. BustosR.H. The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.F1000 Res.20231291410.12688/f1000research.128441.1 38125558
     [Google Scholar]
  59. RuanZ. UngC.O.L. ShenY. ZhangY. WangW. LuoJ. ZouH. XueY. WangY. HuH. GuoL. Long-term cost-effectiveness analysis of once-weekly semaglutide versus dulaglutide in patients with type 2 diabetes with inadequate glycemic control in China.Diabetes Ther.202213101737175310.1007/s13300‑022‑01301‑4 35934763
     [Google Scholar]
  60. AlqahtaniS.S. Community Pharmacists’ opinions towards poor prescription writing in Jazan, Saudi Arabia.Healthcare202198107710.3390/healthcare9081077 34442214
     [Google Scholar]
  61. CaoM. PanC. TianY. WangL. ZhaoZ. ZhuB. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: A pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.Int. J. Clin. Pharm.202345368969710.1007/s11096‑023‑01556‑2 36977858
     [Google Scholar]
  62. LiuL. ChenJ. WangL. ChenC. ChenL. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.Front. Endocrinol. (Lausanne)202213104378910.3389/fendo.2022.1043789 36568085
     [Google Scholar]
  63. MaliG. AhujaV. DubeyK. Glucagon‐like peptide‐1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database.J. Clin. Pharm. Ther.20214619910510.1111/jcpt.13259 32926446
     [Google Scholar]
  64. StottlemyerB.A. McDermottM.C. MinogueM.R. GrayM.P. BoyceR.D. Kane-GillS.L. Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: A pharmacovigilance study.Ther. Adv. Drug Saf.2023142042098623118133410.1177/20420986231181334 37332887
     [Google Scholar]
  65. AlqahtaniS.S. AhmadS. AlamN. Kashan SyedN. SyedM.H. KhardaliA. YasmeenA. AlshahraniA.M. I AlzareaA. AlanaziA.S. Hassan ElnaemM. Healthcare professionals’ awareness, attitudes and practices towards pharmacovigilance and spontaneous adverse drug reaction reporting in Jazan Province, Saudi Arabia: A survey study.Saudi Pharm. J.202331697998810.1016/j.jsps.2023.04.021 37234340
     [Google Scholar]
  66. KhuntiK. Del PratoS. MathieuC. KahnS.E. GabbayR.A. BuseJ.B. COVID-19, Hyperglycemia, and new-onset diabetes.Diabetes Care202144122645265510.2337/dc21‑1318 34625431
     [Google Scholar]
  67. MartensT. BeckR.W. BaileyR. RuedyK.J. CalhounP. PetersA.L. Pop-BusuiR. Philis-TsimikasA. BaoS. UmpierrezG. DavisG. KrugerD. BhargavaA. YoungL. McGillJ.B. AleppoG. NguyenQ.T. OrozcoI. BiggsW. LucasK.J. PolonskyW.H. BuseJ.B. PriceD. BergenstalR.M. CarlsonA. ChambersS. YangS. KirkmanM.S. KassA. FraserR. CushmanT. RamosC. MagarM. WalkerM. Serafin-DokhanS. SalamM. HurstS. CliftonM.J. KravarusicJ. BansalA. FulkersonC. AngL. RichardsonC. Mizokami-StoutK. ReissJ. LeoneV. StifelK. DaileyG. ChangeA. McCallumJ. GarciaM.I. DavisD. LovellC. RootC. TolerF. WilhelmL. EifertR. MurguiaL. CotaB. NguyenL. LipskiR. LawrenceM.K. FournierA. CarterM. HooverS. CohenN. MouseT. RusnakJ. CamposT. NjeruN. ArantT. BeckS.E. BaloA. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin.JAMA2021325222262227210.1001/jama.2021.7444 34077499
     [Google Scholar]
  68. NathanD.M. LachinJ.M. BebuI. BurchH.B. BuseJ.B. CherringtonA.L. FortmannS.P. GreenJ.B. KahnS.E. KirkmanM.S. Krause-SteinraufH. LarkinM.E. PhillipsL.S. Pop-BusuiR. SteffesM. TiktinM. TripputiM. WexlerD.J. YounesN. Glycemia reduction in type 2 Diabetes - Microvascular and cardiovascular outcomes.N. Engl. J. Med.2022387121075108810.1056/NEJMoa2200436 36129997
     [Google Scholar]
  69. ZhangY. YuJ. KahkoskaA.R. WangJ. BuseJ.B. GuZ. Advances in transdermal insulin delivery.Adv. Drug Deliv. Rev.2019139517010.1016/j.addr.2018.12.006 30528729
     [Google Scholar]
/content/journals/cbc/10.2174/0115734072353980250418211500
Loading
Global Trends and Hotspots in Dulaglutide in the Fields of Diabetes, Obesity, and Cardiovascular Research: A Bibliometric Analysis
Curr. Bioact. Compd. 22, E15734072353980 (2026); https://doi.org/10.2174/0115734072353980250418211500
/content/journals/cbc/10.2174/0115734072353980250418211500
/content/journals/cbc/10.2174/0115734072353980250418211500
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): bibliometrics; cardiovascular; diabetes mellitus; Dulaglutide; mapping; obesity

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test